Tagged with Reimbursement

Italy Managing partner of the law firm Herbert Smith Freehills in Italy, Laura Orlando is one of Italy’s leading life sciences specialists, with a focus on IP and regulatory matters.  Together with Sara Balice, one of the firm’s senior associates they examine the Court of Justice of the European Union’s (CJEU) ruling on…

Turkey In Summer 2018, we spoke to Adriano Antonio Treve, then general manager of Roche Turkey, now Area Head Central Eastern Europe, Turkey, Russia, Central Asia, Iran, Pakistan & Indian Subcontinent. Treve provided insights into the main opportunities and challenges of the Turkish market, Roche’s unrivalled commitment to making a difference…

Baltics Andrejs Pantelejevs, head of bureau of the Ministry of Health of Latvia, discusses the importance of channeling the recent EUR 200 million healthcare financing to raising the wages of practitioners, reimbursing expensive innovative medicines in therapeutic areas such as oncology and cardiovascular diseases as well as strengthening e-health. Can you…

Baltics Kuuno Vaher, market access director Baltics and country lead of AstraZeneca Estonia, discusses the liberal attitude towards innovative and highly needed medicines of Estonian regulators and the crucial importance of closer collaboration with payers, which has led the thriving affiliate to have its portfolio reimbursed in the country. Can you…

Canada Imran Ali, senior manager of the pan-Canadian Pharmaceutical Alliance (pCPA) Office, the body that provides dedicated centralized support to the national negotiating process for drug prices, representing all 14 public drug plan jurisdictions in Canada, discusses the mandate of the pCPA, the main achievements so far, as well as the…

Lithuania Marijus Valatka, general manager Lithuania, Latvia and Estonia at Novo Nordisk, explains the current challenges and areas for improvement in diabetes treatment in Lithuania and stresses the company’s commitment to not only bring medicines to the market but also enhance the quality of treatment fort diabetes and other serious chronic…

Poland Wojciech Koziejowski, managing director of Lundbeck Poland, discusses attaining reimbursement in Poland for the first time in ten years and the recent set-up of their global shared service center of more than 200 staff in Krakow. Moreover, he highlights the leading role the company is taking in educating key stakeholders…

Poland Irena Rej, president of the Polish Pharmaceutical Chamber, Farmacja Polska, discusses the trends of the domestic pharmaceutical market and the recent changes to improve the introduction of innovative products. Furthermore, she highlights the strengths of the local OTC industry and the chamber’s role in facilitating active dialogue with key stakeholders…

Austria Robert Sauermann, head of the department of pharmaceutical affairs in the Main Association of Austrian Social Security Institutions, which publishes the national code of reimbursement, provides an in-depth look into how drugs are assessed before being placed onto the reimbursement list as well as the challenges faced when negotiating with…

USA Janet Lynch Lambert, CEO of the Alliance for Regenerative Medicine (ARM), discusses the association’s aims and membership, the importance of creating a supportive reimbursement environment for regenerative medicine, and the huge and expanding need for education in this critical area. What was the initial inspiration behind setting up the Alliance…

Austria Dr. Andrea Podczeck-Schweighhofer, president of the Austrian Society of Cardiology, the representative voice of the Austrian cardiology ecosystem, provides an overview into the challenges associated with research in Austria and how innovation and drug diversity is being stifled under the current reimbursement system. She also gives insights into Austria´s interaction…

Austria Manuel Reiberg, president of the Forum of the Research-Based Pharmaceutical Industry in Austria (FOPI), which represents the 27 leading pharmaceutical innovators in Austria focused on pharmaceutical innovation, discusses the struggles facing drug innovation under the new reimbursement system, as well as the steps that must be taken to bolster the…